Autolus Therapeutics plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing engineered T cell therapies for oncology and autoimmune diseases. The company's approach centers on programming T cells to target specific disease antigens. Its pipeline includes several investigational programs at varying clinical stages, primarily focused on hematologic and solid malignancies. Obecabtagene autoleucel (AUTO1), the most advanced candidate, is being evaluated in Phase 1b/2 trials for adult acute lymphoblastic leukemia, with a separate Phase 1 program in pediatric ALL patients. Additional candidates target peripheral T-cell lymphoma, neuroblastoma, and multiple myeloma.

The company operates as a pre-revenue clinical-stage entity, with no approved products generating commercial revenues. Its business model depends on capital raises and potential partnerships to fund ongoing clinical development and advancement of its product candidates through regulatory approval processes.

Autolus maintains operations across multiple geographies with approximately 647 full-time employees. The company is incorporated and headquartered in London, United Kingdom, with an Nasdaq listing, and has a market capitalization of approximately $0.5 billion.